Related Experiment Video
Updated: Apr 27, 2026

Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring
Published on: December 9, 2010
A critical path approach to advance nanoengineered medical products
Wendy R Sanhai1, Jack Spiegel2, Mauro Ferrari3
1Office of the Commissioner, FDA, United States.
Abstract:
Still needed in nanotechnology is a product development toolkit containing both scientific and business strategies to stimulate innovation. Among the scientific tools envisioned are evaluative and predictive test methods, such as animal- and computer-based predictive models, characterization assays, toxicity tests and quantitative imaging methods to track biodistribution of nanoparticles in complex biological systems. These tools will help bridge scientific gaps and elucidate potential benefits and risks related to use of nanoengineered medical products. In addition, relevant business strategies, if carefully designed, will help overcome many of the hurdles in this field. This article describes some needed scientific/regulatory and business tools of this field and introduces one collaborative effort underway - a Critical Path Initiative [FDA's Critical Path Initiative: //www.fda.gov/oc/initiatives/criticalpath/.] - structured to bridge some existing gaps.:
More Related Videos
Related Concept Videos
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Preclinical Development: Overview
Clinically Relevant Drug Product Specifications: Methods of Establishment
Clinical Trials: Overview
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Drug Products: Biologics, Biosimilars and Interchangeables

